Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multi-Center, Placebo-Controlled, Dose-Escalation Study of the Safety of IMO-2125 in Hepatitis C-Infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin

Trial Profile

A Phase 1, Multi-Center, Placebo-Controlled, Dose-Escalation Study of the Safety of IMO-2125 in Hepatitis C-Infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tilsotolimod (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 11 Mar 2011 Status changed from active, no longer recruiting to completed based on information reported in an Idera Pharmaceuticals media release.
    • 01 Nov 2010 Status changed from recruiting to active, no longer recruiting.
    • 31 Oct 2010 Results have been presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), according to an Idera Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top